HC Wainwright Equities Analysts Boost Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN)

UroGen Pharma Ltd. (NASDAQ:URGN) – Equities researchers at HC Wainwright raised their FY2023 earnings per share (EPS) estimates for UroGen Pharma in a report issued on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($3.43) per share for the year, up from their prior forecast of ($3.49). HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q4 2023 earnings at ($0.61) EPS, Q1 2024 earnings at ($0.58) EPS, Q2 2024 earnings at ($0.55) EPS, Q3 2024 earnings at ($0.43) EPS, Q4 2024 earnings at ($0.39) EPS and FY2024 earnings at ($1.93) EPS.

Other equities analysts have also issued research reports about the company. LADENBURG THALM/SH SH boosted their price objective on UroGen Pharma from $47.00 to $52.00 in a research note on Monday, July 31st. Oppenheimer lowered their price objective on UroGen Pharma from $33.00 to $32.00 and set an “outperform” rating on the stock in a research note on Wednesday.

UroGen Pharma Stock Performance

NASDAQ URGN opened at $12.46 on Friday. The stock’s fifty day moving average is $13.19 and its two-hundred day moving average is $13.64. The firm has a market capitalization of $292.24 million, a P/E ratio of -2.95 and a beta of 0.97. UroGen Pharma has a fifty-two week low of $7.07 and a fifty-two week high of $24.13.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 3,800 shares of UroGen Pharma stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $18.01, for a total value of $68,438.00. Following the sale, the general counsel now owns 18,407 shares in the company, valued at $331,510.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.13% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

Several large investors have recently bought and sold shares of URGN. Rice Hall James & Associates LLC increased its holdings in UroGen Pharma by 6.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 107,990 shares of the company’s stock worth $941,000 after purchasing an additional 6,631 shares during the period. Swiss National Bank increased its holdings in UroGen Pharma by 9.1% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the company’s stock worth $417,000 after purchasing an additional 4,000 shares during the period. JPMorgan Chase & Co. boosted its position in shares of UroGen Pharma by 30.8% during the 1st quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company’s stock worth $714,000 after acquiring an additional 19,280 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of UroGen Pharma by 11.9% during the 1st quarter. Bank of New York Mellon Corp now owns 67,486 shares of the company’s stock worth $588,000 after acquiring an additional 7,197 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of UroGen Pharma during the 1st quarter worth about $215,000. Hedge funds and other institutional investors own 63.42% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.